FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2023/02/049571 [Registered on: 09/02/2023] Trial Registered Prospectively
Last Modified On: 02/02/2023
Post Graduate Thesis  No 
Type of Trial  PMS 
Type of Study   Medical Device 
Study Design  Single Arm Study 
Public Title of Study   A study to check the effect of wound dressing in long standing wounds of leg 
Scientific Title of Study   A prospective, single-arm study to assess the effectiveness and safety of Theruptor Novo dressing pad in the treatment of chronic lower extremity wounds 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
FS-2022-01; V1; 05/12/2022  Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Sanjay Sharma 
Designation  Podiatric Surgeon & Wound Care Specialist  
Affiliation  FootSecure clinic 
Address  FootSecure Clinic, RxDx, Third Floor, Plot No. 7G, Opp. Graphite India, EPIP Zone, Whitefield

Bangalore
KARNATAKA
560048
India 
Phone  9980772658  
Fax    
Email  sanjay@footsecure.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Sanjay Sharma 
Designation  Podiatric Surgeon & Wound Care Specialist  
Affiliation  FootSecure clinic 
Address  FootSecure Clinic, RxDx, Third Floor, Plot No. 7G, Opp. Graphite India, EPIP Zone, Whitefield

Bangalore
KARNATAKA
560048
India 
Phone  9980772658  
Fax    
Email  sanjay@footsecure.com  
 
Details of Contact Person
Public Query
 
Name  Dr Sanjay Sharma 
Designation  Podiatric Surgeon & Wound Care Specialist  
Affiliation  FootSecure clinic 
Address  FootSecure Clinic, RxDx, Third Floor, Plot No. 7G, Opp. Graphite India, EPIP Zone, Whitefield

Bangalore
KARNATAKA
560048
India 
Phone  9980772658  
Fax    
Email  sanjay@footsecure.com  
 
Source of Monetary or Material Support  
Healthium Medtech Limited, 472/D, 13th Cross, 4th Phase, Peenya, Industrial Area, Bengaluru, Karnataka 560058 
 
Primary Sponsor  
Name  Dr Sanjay Sharma  
Address  FootSecure Clinic- RxDx, Third Floor, Plot No. 7G, Opp. Graphite India, EPIP Zone, Whitefield, Bengaluru, Karnataka 560048 
Type of Sponsor  Other [Self] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 3  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Sanjay Sharma  FootSecure Clinic Malleshwaram  RxDx Samanvay, 29, 11th Main Rd, Malleshwaram, 560003
Bangalore
KARNATAKA 
9980772658

sanjay@footsecure.com 
Dr Sanjay Sharma  FootSecure Clinic Sahakaranagar  Foot Secure Clinic, Sahakaranagar, 560092
Bangalore
KARNATAKA 
9980772658

sanjay@footsecure.com 
Dr Sanjay Sharma  FootSecure Clinic Whitefield  RxDx, Third Floor, Plot No. 7G, Opp. Graphite India, EPIP Zone, Whitefield, 560048
Bangalore
KARNATAKA 
9980772658

sanjay@footsecure.com 
 
Details of Ethics Committee  
No of Ethics Committees= 3  
Name of Committee  Approval Status 
Ethics Committee Telerad RxDx Healthcare Pvt. Ltd  Approved 
Ethics Committee Telerad RxDx Healthcare Pvt. Ltd  Approved 
Ethics Committee Telerad RxDx Healthcare Pvt. Ltd  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: L979||Non-pressure chronic ulcer of unspecified part of lower leg,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  3D hydrocellular structure dressing pad  3D hydrocellular dressing pad is made of Polyethylene terephthalate (PET), polyurethane (PU) and Dimethyl Tetradecyl [3(trimethoxysily) propyl] ammonium chloride (DTAC). The wound dressing will be done from visit 1 to visit 9, that is on day 1, 7, 14, 21, 28, 35, 42, 49 and 56 
Comparator Agent  Not applicable  Not applicable 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  99.00 Year(s)
Gender  Both 
Details  1. Male and female patients aged above 18 years with ≤ 3 wounds in the lower extremity considered for the study
2. Patient with a low to moderate exuding lower extremity wound with size ≤ 8 cm × 8 cm, with less than 50% of contraction in the past 4 weeks even after standard treatment
3. Patient willing to give written informed consent and adhere to study procedures
 
 
ExclusionCriteria 
Details  1. Patients with wounds caused by venous or arterial insufficiency, or electrical or chemical burns
2. Patients with wounds showing presence of necrosis, purulence or sinus tracts that cannot be removed by debridement
3. Patients with history of active Charcoat’s foot of the study foot within 6 months of screening
4. Patients with severe or poorly controlled diabetes mellitus with severe hyperglycaemia (HbA1C >12%)
5. Patients with progressive weight loss
6. Patients undergoing treatment with corticosteroids, immunosuppressive or chemotherapeutic agents, or radiotherapy
7. Patients with history of other diseases, which can alter the normal healing of the wound such as connective tissue disease, renal failure, liver failure, and malignancy
8. Patients who underwent revascularization surgery in the last 8 weeks
9. Patients with ankle-brachial index(ABI) < 0.7
10. Pregnant or lactating mothers
 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
The percentage of wound contraction as calculated by using the initial and final area every week for 8 weeks by using graded sterile centimeter ruler sterile scale  Day 7, 14, 21, 28, 35, 42, 49 & 56 
 
Secondary Outcome  
Outcome  TimePoints 
Wound dimensions, wound edge, type of tissue in the wound bed, the depth of the wound, exudate of the wound, Peri-wound skin and presence of infection/inflammation will be assessed by using RESVECH 2.0 scale  Day 1, 7, 14, 21, 28, 35, 42, 49 & 56 
Visual analogue scale (VAS) is used to assess pain every week during dressing pad removal  Day 7, 14, 21, 28, 35, 42, 49 & 56 
Subject satisfaction of wound healing using 5-point scale  Day 7, 14, 21, 28, 35, 42, 49 & 56 
Wound360 version 1.1 application is used for wound characterization and photography  Day 1, 7, 14, 21, 28, 35, 42, 49 & 56 
To assess adverse events  Day 7, 14, 21, 28, 35, 42, 49 & 56 
 
Target Sample Size   Total Sample Size="49"
Sample Size from India="49" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Post Marketing Surveillance 
Date of First Enrollment (India)   15/02/2023 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="0"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   none yet 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Wound healing is a complex sequence of events that begins with injury and ends with successful closure. Wound healing process consists of a highly integrated and overlapping phases that is critical in maintaining the normal function of skin. Wound treatment is different in everybody and often depends on the number of factors. Age, skin type, type of wound, location, and severity are some of the factors which depends on treating wound and avoiding infection.

 

With many disease processes, the cascade of events involved in wound healing can be affected, resulting in chronic, non-healing wounds. All wounds have the potential to become chronic wounds. Understanding and addressing the challenges in the treatment of chronic wounds will lead to a better clinical outcome (faster and more durable wound closure), and avoid inappropriate treatment that may cause deterioration of the wound, delay wound healing, or harm the patient, resulting in improved patient quality of life and reduced healthcare costs. 

The ideal dressing should keep the wound moist but not macerated, limit bacterial overgrowth, keep odour to a minimum, and be comfortable to wear. Important criteria to consider before choosing a specific wound dressing are cleaning, absorbing, regulating, and the need to add medication. It is important that the dressings be removed atraumatically, to avoid further damage to the wound surface during dressing changes

Theruptor Novo is a sterile barrier wound dressing intended for use as a primary dressing for exuding wounds, first and second degree burns, minor wounds and surgical wounds; to secure and prevent movement of a primary dressing; and as a wound packing. It is a 3D hydrocellular structure (moisture management) dressing pad, which is made of Polyethylene terephthalate, polyurethane and Dimethyl Tetradecyl [3(trimethoxysily) propyl] ammonium chloride (DTAC) for antimicrobial action. 

·     This study is done to assess the efficacy and safety of Theruptor Novo dressing pad in patients with chronic lower extremity wound


 
Close